Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131, USA.
Endocrinology. 2011 Aug;152(8):3030-9. doi: 10.1210/en.2011-0091. Epub 2011 Jun 14.
Sexual dimorphism and supplementation studies suggest an important role for estrogens in the amelioration of glucose intolerance and diabetes. Because little is known regarding the signaling mechanisms involved in estradiol-mediated insulin secretion, we investigated the role of the G protein-coupled receptor 30, now designated G protein-coupled estrogen receptor (GPER), in activating signal transduction cascades in β-cells, leading to secretion of insulin. GPER function in estradiol-induced signaling in the pancreatic β-cell line MIN6 was assessed using small interfering RNA and GPER-selective ligands (G-1 and G15) and in islets isolated from wild-type and GPER knockout mice. GPER is expressed in MIN6 cells, where estradiol and the GPER-selective agonist G-1 mediate calcium mobilization and activation of ERK and phosphatidylinositol 3-kinase. Both estradiol and G-1 induced insulin secretion under low- and high-glucose conditions, which was inhibited by pretreatment with GPER antagonist G15 as well as depletion of GPER by small interfering RNA. Insulin secretion in response to estradiol and G-1 was dependent on epidermal growth factor receptor and ERK activation and further modulated by phosphatidylinositol 3-kinase activity. In islets isolated from wild-type mice, the GPER antagonist G15 inhibited insulin secretion induced by estradiol and G-1, both of which failed to induce insulin secretion in islets obtained from GPER knockout mice. Our results indicate that GPER activation of the epidermal growth factor receptor and ERK in response to estradiol treatment plays a critical role in the secretion of insulin from β-cells. The results of this study suggest that the activation of downstream signaling pathways by the GPER-selective ligand G-1 could represent a novel therapeutic strategy in the treatment of diabetes.
性二态性和补充研究表明雌激素在改善葡萄糖耐量和糖尿病方面起着重要作用。由于对涉及雌二醇介导胰岛素分泌的信号转导机制知之甚少,我们研究了 G 蛋白偶联受体 30(现在称为 G 蛋白偶联雌激素受体(GPER))在激活β细胞胰岛素分泌信号转导级联中的作用。使用小干扰 RNA 和 GPER 选择性配体(G-1 和 G15)以及从野生型和 GPER 敲除小鼠分离的胰岛评估了 GPER 在胰岛β细胞系 MIN6 中雌二醇诱导的信号转导中的作用。GPER 在 MIN6 细胞中表达,其中雌二醇和 GPER 选择性激动剂 G-1 介导钙动员和 ERK 和磷酸肌醇 3-激酶的激活。雌二醇和 G-1 在低糖和高糖条件下均诱导胰岛素分泌,GPER 拮抗剂 G15 的预处理以及小干扰 RNA 耗竭 GPER 均可抑制胰岛素分泌。对雌二醇和 G-1 的胰岛素分泌反应依赖于表皮生长因子受体和 ERK 激活,并进一步受磷酸肌醇 3-激酶活性的调节。在从野生型小鼠分离的胰岛中,GPER 拮抗剂 G15 抑制了雌二醇和 G-1 诱导的胰岛素分泌,而这两种物质均未能诱导从 GPER 敲除小鼠获得的胰岛中的胰岛素分泌。我们的结果表明,GPER 对表皮生长因子受体和 ERK 的激活响应雌二醇处理在β细胞胰岛素分泌中起关键作用。这项研究的结果表明,GPER 选择性配体 G-1 激活下游信号通路可能代表治疗糖尿病的一种新的治疗策略。